Share on
The ILCS 2025 was made possible by unrestricted educational grants from our sponsors:
Explore MSD's Booth
Explore Amgen's Booth
Visit JnJ
Visit PharmaMar
Visit AstraZeneca
RELATED
Explore More
Sep
26
2025
SCLC
RESHAPING APPROACHES IN SCLC WITH THE LATEST ADVANCES IN LS- AND ES-DISEASE
34 min
Sep
26
2025
METASTATIC NSCLC
LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND
32 min
Sep
26
2025
IMMUNOTHERAPIES
THE ROLE OF IO ADDED TO CHEMORADIATION IN UNRESECTABLE STAGE III NSCLC
28 min
Sep
26
2025
IMMUNOTHERAPIES
TAILORING IO IN RES. NSCLC: PERSONALIZED APPROACHES FOR IMPROVED OUTCOMES
36 min
Sep
26
2025
INDUSTRY SYMPOSIUM
UNLOCKING NEW POTENTIALS IN EGFR-MUTANT NSCLC
30 min
Sep
26
2025
ADCs
THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES
27 min
Sep
26
2025
TARGETED THERAPIES
DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?
31 min
Sep
26
2025
TARGETED THERAPIES
ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET
26 min
Sep
26
2025
TARGETED THERAPIES
TARGETING EGFR AND ALK IN NSCLC
26 min
Sep
26
2025
BIOMARKERS
CUTTING-EDGE DIAGNOSTIC TECHNIQUES AND EMERGING BIOMARKERS
24 min
Sep
26
2025
METASTATIC NSCLC
Open Discussion on Patient Cases
22 min
